References
- World Health Organisation. Skin cancers. [cited 12 December 2019]. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html
- Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–2269.
- Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
- Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58(9):1798–1803.
- Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005;65(19):8597–8603.
- Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–754.
- Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Head Neck Pathol. 2016;10(2):119–124.
- European Medicines Agency. Erivedge summary of product characteristics, February 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf
- Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.
- Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348.
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 2). 2017. [cited September 2019]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2). 2017. [cited September 2019]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162051.pdf
- Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharmaceut Med. 2017;31(2):101–112.
- Lipinski RJ, Hutson PR, Hannam PW, et al. Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci. 2008;104(1):189–197.
- Tang JC, Hanke CW, Caro I. Vismodegib and the Hedgehog pathway inhibitors: a historical perspective to current clinical application. J Drugs Dermatol. 2018;17(5):506–508.
- Madison T, Donner B, Mutter R, et al. Effectiveness of risk minimization measures to prevent pregnancy exposure to mycophenolate-containing medicines in Europe. Pharm Med. 2019;33(5):395–406.
- Toussi M. Evaluation of the effectiveness of risk minimisation measures: a survey among health care professionals to assess their knowledgeand attitudes on prescribing conditions of Instanyl® in France and the Netherlands 2016. [cited September 2019]. Available from: http://www.encepp.eu/encepp/openAttachment/studyResult/16235
- Lem J. Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of photoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in the European Union (EU) 2016. [cited September 2019]. Available from: http://www.encepp.eu/encepp/openAttachment/studyResult/13665
- Felo L, Otero-Lobato M, Geldhof A, et al. Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan. Ther Adv Drug Saf. 2019;10:2042098619847420.